Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | BTK | Q06187 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 4/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.45 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22135125 | 0.97 | KDR (0.49) | KDREPHB4EPHA2JAK3BTK | |
| SCHEMBL9937994 | 0.91 | KDR (0.50) | KDREPHB4EPHA2EGFRHTR2C | |
| SCHEMBL9972390 | 0.83 | KDR (0.56) | KDREPHB4EPHA2EGFRHTR2C | |
| SCHEMBL9939341 | 0.80 | L3MBTL1 (0.43) | MAPTFLT3 | |
| SCHEMBL31592579 | 0.77 | IGF1R (0.66) | KDREPHB4JAK3BTKEGFR | |
| SCHEMBL6483193 | 0.77 | KDR (0.57) | KDREPHB4EPHA2JAK3BTK | |
| SCHEMBL22163326 | 0.76 | JAK3 (0.49) | KDREPHB4EPHA2JAK3BTK | |
| SCHEMBL3627848 | 0.76 | MAPT (0.52) | EPHB4MAPTMAPK9MAPK10 | |
| SCHEMBL20124547 | 0.76 | EPHA2 (0.50) | KDREPHB4EPHA2JAK3EGFR | |
| SCHEMBL25942432 | 0.75 | EGFR (0.45) | EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651416-B1 | COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2018-05-09 | — | — | EP | claimed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | claimed |
| EP-2651416-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | Splicos (FR) | 2013-10-23 | — | — | EP | claimed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | claimed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | claimed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | claimed |
| WO-2023139233-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-27 | — | — | WO | disclosed |
| EP-4215196-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2022-01-27 | — | — | US | disclosed |
| WO-2020127853-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR3, CBR1, CCR10 | KDR 3471/4885EPHB4 2323/4885EPHA2 3227/4885 |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR1H3, NR1H2, NR1H4 | KDR 2235/4885EPHB4 1781/4885EPHA2 2134/4885 |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | HAVCR2, CXCL8, IL36G | KDR 1114/4885EPHB4 2462/4885EPHA2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.